Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,951 public trials 2,018 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Recruiting

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

NCT05651932

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • UCSF Medical Center - Hematology and Blood and Marrow Transplant Clinic San Francisco, California, United States
  • Mayo Clinic Hospital - Florida Jacksonville, Florida, United States
  • The Winship Cancer Institute of Emory University Atlanta, Georgia, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
View all 22 locations
View Trial Details
Recruiting

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)

NCT07234162

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Anhui Provincial Cancer Hospital Hefei, Anhui, China
  • The Second Hospital of Anhui Medical University Hefei, Anhui, China
  • Beijing Hospital Beijing, Beijing Municipality, China
  • Beijing Tongren Hospital, CMU Beijing, Beijing Municipality, China
View all 51 locations
View Trial Details
Recruiting

Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM

NCT06561347

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Colorado Blood Cancer Institute (CBCI) Denver, Colorado, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Recruiting

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

NCT06697184

Conditions
CLL, Chronic Disease, Chronic Lymphocytic Leukemia, +22 more
Locations
  • Moffitt Cancer Center Tampa, Florida, United States
  • Fort Wayne Medical Oncology and Hematology Fort Wayne, Indiana, United States
  • The University of Kansas Cancer Center Westwood, Kansas, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View all 17 locations
View Trial Details

Related conditions